Recent research progress in cardiovascular effects of endothelin

Abstract

Abstract: Endothelin is the most powerful vasoconstrictor substance so far and widely distributed in peripheral tissue and central nervous system. It is an important factor in regulating cardiovascular function and keeping cardiovascular homeostasis and vascular tone. The pathogenesis of many cardiovascular diseases are associated with abnormal function of the endothelin system. This review summarizes the research progress of the cardiovascular effects of endothelin in recent years.

Key words: Endothelin, Endothelin receptor antagonists, Cardiovascular effects

CLC Number:

R966

CHEN Ai-dong, LI Juan, XIE Hai-tang. Recent research progress in cardiovascular effects of endothelin[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(8): 937-944.

References

[1] Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells[J]. Nature, 1988, 332(6163): 411-415.
[2] Burg MM, Soufer A, Lampert R, et al. Autonomic contribution to endothelin-1 increase during laboratory anger-recall stress in patients with coronary artery disease[J]. Mol Med, 2011, 17(5/6): 495-501.
[3] Freixa X, Heras M, Ortiz JT, et al. Usefulness of endothelin-1 assessment in acute myocardial infarction[J]. Rev Esp Cardiol, 2011, 64(2): 105-110.
[4] Crockett TR, Scott GA, McGowan NW, et al. Anti-arrhythmic an electrophysiological effects of the endothelin receptor antagonists, BQ-123 and PD161721[J]. Eur J Pharmacol, 2001, 432 (1): 71-77.
[5] Dobrek Ł, Thor P. Neuroendocrine activation as a target of modern chronic heart failure pharmaco- therapy[J]. Acta Pol Pharm, 2011, 68(3): 307-316.
[6] An SJ, Boyd R, Zhu M, et al. NADPH oxidase mediates angiotensin II-induced endothelin-1 expression in vascular adventitial fibroblasts[J]. Cardiovasc Res, 2007, 75(4): 702-709.
[7] Park JB, Schiffrin EL. ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats[J]. Hypertention, 2001, 37(6): 1444-1449.
[8] Kanagy NL, Walker BR, Nelin LD. Role of endothelin in intermittent hyoxia-induced hypertension[J]. Hypertension, 2001, 37 (part 2): 511-515.
[9] Krum H, Viskoper RJ, Lacourciere Y, et al. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension[J]. N Engl J Med, 1998, 338(12): 784-790.
[10] Schalcher C, Cotter G, Reisin L, et al. The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure[J]. Am Heart J, 2001, 42(2): 340-349.
[11] Miki S, Takeda K, Kiyama M, et al. Modulation of endothelin-1 coronary vasoconstriction in spontan- eously hypertensive rats by the nitricoxide system[J]. Am J Hypertens, 2000, 13(1): 83-87.
[12] Alberola AM, Revert F, Moya A, et al. Intravenous BQ-123 and Phosphoramidon reduce ventricular ectopic beats and myocardial infart size in dogs submitted to coronary occlusion and reperfusion[J]. Gen Pharmacol, 2000, 35 (3): 143-147.
[13] Kopp UC, Cicha MZ, Jones SY. Activation of endothelin A receptors contributes to impaired responsiveness of renal mechanosensory nerves in congestive heart failure[J]. Can J Physiol Pharmacol, 2010, 88(6): 622-629.
[14] Tirapelli CR, Fecteau MH, Honore JC, et al. Enzymatic pathways involved in the generation of endothelin-1(1-31) from exogenous big endothelin-1 in the rabbit aorta[J]. Br J Pharmacol, 2006, 148(4): 527-535.
[15] Levin ER. Endothelins[J]. N Engl J Med, 1995, 333(10): 356-363.
[16] Turner AJ, Barnes K, Schweizer A, et al. Isoforms of endothelinconverting enzyme: why and where[J] ? Trends Pharmacol Sci, 1998, 19(12): 483-486.
[17] Kuwaki T, Cao WH, Kumada M. Endothelin in the brain and its effect on central control of the circulation and other functions[J]. Jpn J Physiol, 1994, 44(1): 1-18.
[18] Rodríguez-Pascual F, Busnadiego O, Lagares D, et al. Role of endothelin in the cardiovascular system[J]. Pharmacol Res, 2011, 63(6): 463-472.
[19] Yoshimi H, Kawano Y, Akabane S, et al. Immunoreactive endothelin-1 contents in brain regions from spontaneously hypertensive rats[J]. J Cardiovasc Pharmacol, 1991, 17(Suppl 7): S417-419.
[20] Rossi NF, Chen H. PVN lesions prevent the endothelin-1 induced increase in arterial pressure and vasopressin[J]. Am J Physiol Endocrinol Metab, 2001, 280(2): E349-E356.
[21] Höltke C, Waldeck J, Kopka K, et al. Biodistribution of a nonpeptidic fluorescent endothelin a receptor imaging probe[J]. Mol Imaging, 2009, 8(1): 27-34.
[22] Pedersen SH, Nielsen LB, Pedersen NG, et al. Hormone therapy modulates ET(A) mRNA expression in the aorta of ovariectomised New Zealand White rabbits[J]. Gynecol Endocrinol, 2009, 25(3): 175-182.
[23] Lindstedt I, Xu CB, Zhang Y, et al. Increased perfusion pressure enhances the expression of endothelin (ETB) and angiotensin II (AT1, AT2) receptors in rat mesenteric artery smooth muscle cells[J]. Blood Press, 2009, 18(1): 78-85.
[24] Palmer MJ. Endothelin receptor antagonists: status and learning 20 years on[J]. Prog Med Chem, 2009, 47: 203-237.
[25] Higazi DR, Fearnley CJ, Drawnel FM, et al. Endothelin-1-stimulated InsP3-induced Ca²⁺ release is a nexus for hypertrophic signaling in cardiac myocytes[J]. Mol Cell, 2009, 33(4): 472-482.
[26] Li L, Fink GD, Watts SW, et al. Endothelin-1 increases vascular superoxide via endothelin (A)-NADPH oxidase pathway in low-renin hypertension[J]. Circulation, 2003, 107(7): 1053-1058.
[27] Dai X, Galligan JJ, Watts SW, et al. Increased O2 production and upregulation of ETB receptors by sympathetic neurons in DOCA-salt hypertensive rats[J]. Hypertension, 2004, 43(5): 1048-1054.
[28] Dong F, Zhang X, Wold LE, et al. Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: role of ETB cell receptor, NADPH oxidase and caveolin-1[J]. Br J Pharmacol, 2005, 145(3): 323-333.
[29] Callera GE, Tostes RC, Yogi A, et al. Endothelin-1-induced oxidative stress in DOCA-salt hyperten- sion involves NADPH-oxidase-independent mechanisms[J]. Clin Sci, 2006, 110(2): 243-253.
[30] Sedeek MH, Llinas MT, Drummond H, et al. Role of reactive oxygen species in endothelin-induced hypertension[J]. Hypertension, 2003, 42(4): 806-810.
[31] Ruef J, Moser M, Kubler W, et al. Induction of endothelin-1 expression by oxidative stress in vascular smooth muscle cells[J]. Cardiovasc Pathol, 2001, 10(6): 311-315.
[32] Li L, Watts SW, Banes AK, et al. NADPH oxidase-derived superoxide augments endothelin-1-induced venoconstriction in mineralocorticoid hypertension[J]. Hypertension, 2003, 42(3): 316-321.
[33] Hirotani S, Higuchi Y, Nishida K, et al. Ca²⁺ sensitive tyrosine kinase Pyk2/CAK beta-dependent signaling is essential for G-protein-coupled receptor agonist-induced hypertrophy[J]. J Mol Cell Cardiol, 2004, 36(6): 799-807.
[34] Daou GB, Srivastava AK. Reactive oxygen species mediate endothelin-1-induced activation of ERK1/2, PKB, and Pyk2 signaling, as well as protein synthesis, in vascular smooth muscle cells[J]. Free Radic Biol Med, 2004, 37(2): 208-215.
[35] Lu Y, Wang LG, Liao Z, et al. Cardiovascular effect s of centrally applied endot helin21(1-31) and its relationship to endothelin-1(1-21) in rats[J]. Auton Neurosci, 2007, 133(2): 146-152.
[36] Rossi NF, Maliszewska-Scislo M. Role of paraventricular nucleus vasopressin V1A receptors in the response to endothelin 1 activation of the subfornical organ in the rat[J]. J Physiol Pharmacol, 2008, 59 (Suppl 8): 47-59.
[37] Lu Y, Wang WZ, Liao Z, et al. Blood pressure responses of endothelin-1 (1-31) within the rost ralvent rolateral medulla through conversion to endothelin-1(1-21)[J]. J Cardiovasc Pharmacol, 2005, 46(6): 823-829.
[38] Isaka M, Kudo A, Imamura M, et al. Endothelin receptors, localized in sympathetic nerve terminals of the heart, modulate norepinephrine release and reperfusion arrhythmias[J]. Basic Res Cardiol, 2007, 102(2): 154-162.